Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSI-Immune: Patient Preference for Subcutaneous vs. Intravenous Nivolumab or Pembrolizumab
NCT07223424Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab (subcutaneous), pembrolizumab in solid tumor. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07223424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223424.